SPOTLIGHT: Acorda announces added trial

Acorda Therapeutics has announced an additional late-stage trial of Fampridine-SR for multiple sclerosis. Researchers are working with the FDA to design a new Phase III study of the same or shorter duration as the recently completed trial. That study demonstrated that volunteers taking the drug experienced significantly improved walking speed. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.